FeesSafety
Pluang+

IXICO shares jump 19% on strong revenue growth and record order book

Market News
20 Oct 2026, 12:49 WIB
Proactive Investors
View Source
Bullish
IXICO shares jump 19% on strong revenue growth and record order book

IXICO PLC, a medical imaging and data analytics firm, saw its shares rise over 19% after forecasting 28% revenue growth to £8.3 million for the year ending September 2026, surpassing broker expectations. The company also reported a record year-end order book of £16 million, up from £13.8 million the previous year, and expects a smaller EBITDA loss than anticipated. Broker Cavendish rates IXICO as a 'buy' with a target price implying a 235% upside, highlighting the firm's consistent double-digit revenue growth and promising TechBio strategy. Final results are expected in December, which may lead to updated forecasts.

IXICO shares jump 19% as revenue growth and order book strengthen. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 20, 2026 15:51 WIB: Out of 150 priced US health stocks, 80 rose and 61 fell. Notable movers include HRTX at USD 0.36 with a 1-day change of -2.63%, BKD at USD 10.08 up 2.23%, and SNY at USD 40.44 up 2.20%.

More News

SI-BONE Q3 revenue rises 15% to $55.7M; new Onyx device expands market to $5B

SI-BONE Q3 revenue rises 15% to $55.7M; new Onyx device expands market to $5B

SI-BONE reported a 15% increase in third-quarter 2026 revenue to $55.7 million, driven by growing adoption of its surgical implants. The launch of the iFuse Granite Onyx device, approved by the FDA, expands the company's addressable market to $5 bill...

Company Fundamentals
Bullish
16 minutes ago
Nvidia, Coherent, and Dell report strong AI-driven growth despite recent stock drops.

Nvidia, Coherent, and Dell report strong AI-driven growth despite recent stock drops.

Nvidia, Coherent, and Dell Technologies all supply key components for AI infrastructure and have reported strong revenue growth despite significant stock price declines. Nvidia's data center revenue rose 21% sequentially, with a fiscal Q4 revenue for...

Bullish
30 minutes ago
BridgeBio's Attruby revenue soars 134% YoY; FDA decision for BBP-418 due Nov 27

BridgeBio's Attruby revenue soars 134% YoY; FDA decision for BBP-418 due Nov 27

BridgeBio reported a 134% year-over-year increase in net product revenue for Attruby, reaching $253.2 million in Q3 2026, driven by new patients starting treatment for transthyretin amyloid cardiomyopathy. The company anticipates an FDA decision on N...

Company Fundamentals
Bullish
58 minutes ago
Altria raises dividends for 57 years but faces declining cigarette sales and high payout risks.

Altria raises dividends for 57 years but faces declining cigarette sales and high payout risks.

Altria Group has increased its dividends for 57 consecutive years, maintaining a strong yield of 5.9%, well above the S&P 500 average. However, the company's cigarette sales volumes continue to decline, with a 2.8% drop in cigarette volume this year ...

Company Fundamentals
Neutral
59 minutes ago
Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth reported $1.03 billion in revenue for Q3 2026, surpassing company guidance. The firm sees enterprise software as the key channel for AI deployment, with strong growth in cybersecurity and risk bookings, up over 40% year-to-date due to incre...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App